Valuation: Arcus Biosciences, Inc.

Market Cap 3.55B 3.08B 2.87B 2.63B 4.97B 338B 5.05B 33.82B 13.27B 168B 13.32B 13.02B 565B P/E 2026 *
-7.67x
P/E 2027 * -8.36x
Enterprise Value 2.92B 2.54B 2.37B 2.17B 4.1B 279B 4.17B 27.89B 10.95B 139B 10.98B 10.74B 466B EV / Sales 2026 *
34.4x
EV / Sales 2027 * 35.3x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day-0.21%
1 week-0.81%
1 month-8.56%
3 months+10.55%
6 months+33.98%
Current year+18.30%
1 week 26.19
Extreme 26.19
29.63
1 month 25.68
Extreme 25.68
31.23
Current year 18.52
Extreme 18.515
31.74
1 year 8.88
Extreme 8.88
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 72 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
10/7/26 Sell

Founder

-20,067 0.0160%
11/6/26 Free

Director

22,600 0.0180%
23/1/26 Free

Chief Financial Officer

157,000 0.1269%
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-0.81%+208.76%+41.66% 3.55B
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average -1.37%+0.87%+76.02%+96.43% 25.4B
Weighted average by Cap. -1.58%+1.99%+78.83%+126.81%

Financials

2026 *2027 *
Net sales 85.06M 73.94M 68.83M 63.19M 119M 8.12B 121M 811M 318M 4.04B 319M 312M 13.56B 93.06M 80.89M 75.3M 69.13M 131M 8.88B 133M 888M 348M 4.42B 349M 342M 14.83B
Net income -456M -397M -369M -339M -640M -43.57B -650M -4.35B -1.71B -21.69B -1.71B -1.68B -72.73B -431M -374M -348M -320M -604M -41.1B -613M -4.11B -1.61B -20.46B -1.62B -1.58B -68.61B
Net Debt -621M -540M -503M -462M -872M -59.31B -885M -5.93B -2.33B -29.53B -2.33B -2.28B -99.01B -259M -225M -210M -193M -364M -24.76B -369M -2.47B -971M -12.33B -974M -953M -41.33B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
31/07/26 US$28.19 -0.21% 1,271,569
30/07/26 US$28.25 +6.81% 813,637
29/07/26 US$26.45 -2.22% 856,162
28/07/26 US$27.05 -2.84% 1,580,324
27/07/26 US$27.84 -2.04% 1,268,818
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
28.19USD
Average target price
36.83USD
Spread / Average Target
+30.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock